Summary
The product Anapolon Oxymetholone, manufactured by Vulkan Pharmaceuticals, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number LOT: 4TQ91Z, was submitted by the manufacturer vulkanpharma@proton.me and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Oxymetholone, with a concentration of 22.93 mg, which is below the typical expected dosage for this product.
The testing process was conducted on 13 November 2024. While the results indicate the presence of the active ingredient, the lower-than-expected concentration raises concerns about the product’s quality and consistency. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Vulkan Pharmaceuticals
- Product Name: Anapolon Oxymetholone
- Active Ingredient: Oxymetholone
- Batch Number: LOT: 4TQ91Z
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #52518
- Testing Ordered: 29 October 2024
- Sample Received: 5 November 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Vulkan Pharmaceuticals (Manufacturer)
- Analysis Paid For By: Vulkan Pharmaceuticals (Manufacturer)
Testing Results
- Specification: 20 mg/ml
- Oxymetholone Concentration: 22.93 mg
- Accuracy: 91.72% (8.28% below the typical label claim)
- Variance: -8.28%
Verification Details
- Verification URL: https://janoshik.com/tests/52518_DFBYT9L6T8KB
Evaluation of Manufacturer-Submitted Testing
This analysis highlights the presence of Oxymetholone in the tested product but raises concerns due to the lower-than-expected concentration. The sample was submitted by the manufacturer, which may introduce biases in the selection of the batch for testing. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple batches.
Conclusion
The analysis confirms the presence of Oxymetholone in the sample, but the concentration of 22.93 mg is below the typical expected dosage for this product. This result suggests potential issues with quality control and underscores the importance of additional testing to ensure consistent dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding anabolic steroid products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
